Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To examine the association between fetal major heart defects and high nuchal translucency thickness (NT), tricuspid regurgitation and abnormal flow in the ductus venosus in a large population of singleton pregnancies undergoing a routine ultrasound examination at 11‐13 weeks' gestation.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>This was a retrospective study of prospectively collected data from singleton pregnancies attending for a routine ultrasound scan at 11‐13 weeks' gestation which included examination of fetal anatomy, measurement of NT, and assessment of blood flow across the tricuspid valve and in the ductus venosus according to a standardized protocol. The incidence of fetal NT ≥95<sup>th</sup> and NT ≥99<sup>th</sup> percentile, tricuspid regurgitation and reversed a‐wave in the ductus venosus in fetuses with and without major heart defects was determined and the performance of each marker and their combination in the detection of major heart defects was calculated. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The study population of 93,209 pregnancies with no apparent chromosomal abnormality included 211 (0.23%) with major heart defects and 92,998 morphologically normal neonates. In 113 (53.6%) of the major heart defects the diagnosis was made at the 11‐13 weeks scan, in 82 (38.9%) at the 18‐24 weeks scan, in 10 (4.7%) at the third‐trimester scan and in 6 (2.8%) postnatally. At the 11‐13 weeks scan we diagnosed all cases of tricuspid or pulmonary atresia and polyvalvular dysplasia, >90% of cases of hypoplastic left heart syndrome or atrioventricular septal defect, about 60% of complex heart defects and left atrial isomerism (interrupted inferior vena cava with normal intracardiac anatomy), 30‐40% of tetralogy of Fallot and arch abnormalities, 25% of tricuspid valve abnormalities, about 15% of transposition of great arteries, but none of aortic or pulmonary stenosis and common arterial trunk. Fetal NT ≥95<sup>th</sup> percentile, NT ≥99<sup>th</sup> percentile, tricuspid regurgitation, or abnormal ductus venosus flow was observed in 77 (36.5%), 45 (21.3%), 61 (28.9%), and 58 (27.5%) of the fetuses with major heart defects, respectively, and in 5,678 (6.1%), 857 (0.9%), 1,136 (1.2%), and 1,644 (1.8%) of those without heart defects. Any one of NT ≥95<sup>th</sup>, tricuspid regurgitation or abnormal flow in the ductus venosus was found in 117 (55.5%, 95% CI 48.5–62.3%) of the fetuses with heart defects and in 8,166 (8.8%, 95% CI 8.6‐9.0%) of those without heart defects. Any one of NT ≥99<sup>th</sup> percentile and the other two markers was found in 99 of the fetuses with heart defects (46.9%, 95% CI 40.0‐53.9%) and in 3,517 of those without heart defects (3.8%, 95% CI 3.7‐3.9%). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>At 11‐13 weeks' gestation measurement of fetal NT and assessment of flow across the tricuspid valve and in the ductus venosus can lead to the early diagnosis of major heart defects.</p><p>This article is protected by copyright. All rights reserved.</p></section>

Screening for Twin-twin Transfusion Syndrome at First Trimester

Retrospective validation of 11–13 weeks’ gestation ultrasound characteristics as predictive tools for twin-twin transfusion syndrome and selective intrauterine growth restriction in monochorionic diamniotic twin pregnancies

Twin-twin Transfusion Syndrome is Associated with Alterations in the Metabolic Profile of Maternal Plasma in Early Gestation: a Pilot Study.

Velamentous cord insertion in monochorionic twin pregnancies: a step forward in screening for twin to twin transfusion syndrome and birthweight discordance?

Predictive value of nuchal translucency thickness and blood flow spectrum of ductus venous for fetal congenital cardiac malformation in early pregnancy

Difference in Nuchal Translucency Between Monozygotic and Dizygotic Spontaneously Conceived Twins

Value of Umbilical Artery Resistance Index in Prenatal Diagnosis of Twin-Twin Transfusion Syndrome

Maternal Utero-Placental Perfusion Discordance in Monochorionic-Diamniotic Twin Pregnancies with Selective Growth Restriction Assessed by Three-Dimensional Power Doppler Ultrasound

Study on the Application of Ultrasonography in the Diagnosis of Fetal Cardiac Structural Abnormalities and the Relationship Between Fetal Cardiac Structural Abnormalities with Chromosome Abnormalities in Early Pregnancy.

Early Diagnosis Of Trisomy 21, Trisomy 18 And Trisomy 13 Using Nuchal Translucency Thickness And Ductus Venosus Blood Flow Waveform In West China

Relationship Between Nuchal Translucency Thickness and Chromosomal Abnormalities in Fetus

The role of nuchal translucency in prenatal screening

The Effect of Vanishing Twin on First- and Second-Trimester Maternal Serum Markers and Nuchal Translucency: A Multicenter Prospective Cohort Study

[Study on Several Ultrasound Markers Combined Maternal Serum Biochemical Markers to Screen Fetal Chromosomal Aneuploidy at 11 to 13(+)6 Weeks of Gestation].

The Relationship Between Fetal Tricuspid Regurgitation at 11 to 13+6 Week Scan and Chromosomal Defects

Application progress of prenatal ultrasound in twin-twin transfusion syndrome

Diagnosis of major heart defects by routine first‐trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus

Predicting Adverse Outcomes in Monochorionic-Diamniotic Twins: The Role of Intertwin Discrepancy in Middle Cerebral Artery Doppler Measurements and the Cerebroplacental Ratio

Model predicted Down syndrome detection rates for nuchal translucency screening in twin pregnancies

Adverse pregnancy outcome in fetuses with early increased nuchal translucency: prospective cohort study

Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening